Allworth Financial LP Summit Therapeutics Inc. Transaction History
Allworth Financial LP
- $17.3 Billion
- Q4 2024
A detailed history of Allworth Financial LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Allworth Financial LP holds 370 shares of SMMT stock, worth $7,307. This represents 0.0% of its overall portfolio holdings.
Number of Shares
370
Previous 1,022
63.8%
Holding current value
$7,307
Previous $22,000
72.73%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$482 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$230 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$130 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$111 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.97B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...